mScarlet/LUC Reporter Cell Line - ACHN

The ACHN cell line is a widely utilized human model of renal cell carcinoma (RCC), originally established from a malignant pleural effusion of a patient with metastatic kidney cancer. It serves as a cornerstone in urological oncology research, highly valued for its ability to replicate the complex biology and aggressive metastatic nature of advanced renal malignancies. The mScarlet/Luc Reporter Cell Line - ACHN is a sophisticated, stably transfected derivative explicitly engineered to simultaneously co-express both the exceptionally bright, monomeric red fluorescent protein mScarlet and firefly luciferase (Luc). This advanced dual-labeling construct ensures continuous, high-level expression of both functional reporter genes across sequential in vitro passages. Crucially, this stable genetic integration is achieved without compromising the fundamental epithelial morphology, the distinct molecular profile, or the intrinsic tumorigenic and metastatic capacity of the original parental ACHN cells.

The incorporation of this dual-reporter system significantly broadens the experimental utility of the ACHN model for comprehensive translational renal cancer research. For in vitro studies, the intense red fluorescence provided by mScarlet expression allows researchers to easily visualize cellular dynamics, accurately quantify proliferation rates, and seamlessly isolate specific cellular subpopulations using standard fluorescence microscopy and flow cytometry techniques. For in vivo applications, robust luciferase activity provides the optimal basis for non-invasive, longitudinal tracking of primary tumor progression and distant metastatic dissemination via bioluminescence imaging (BLI). Because it is a human-derived cell line, the ACHN-mScarlet/Luc model is typically engrafted into immunocompromised mice (such as athymic nude or NSG strains) to establish highly reliable subcutaneous xenografts, clinically relevant orthotopic renal models, or robust models of experimental metastasis. This specialized reporter line represents an exceptionally valuable platform for evaluating the in vivo therapeutic efficacy of novel chemotherapeutic regimens, targeted pharmacological compounds (such as tyrosine kinase inhibitors), and emerging biotherapeutics, facilitating the real-time, accurate quantification of localized tumor burden and disseminated disease in living subjects.